Maja Kopczynska1, Wioleta M Zelek1, Simone Vespa1, Samuel Touchard1, Mark Wardle2, Samantha Loveless2, Rhys H Thomas3, Khalid Hamandi2, B Paul Morgan4. 1. Systems Immunity Research Institute and Division of Psychological Medicine and Clinical Neurology, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK. 2. Department of Neurology, University Hospital of Wales, Cardiff, CF14 4XW, UK. 3. Department of Neurology, University Hospital of Wales, Cardiff, CF14 4XW, UK; Institute of Neuroscience, Henry Wellcome Building, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. 4. Systems Immunity Research Institute and Division of Psychological Medicine and Clinical Neurology, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK. Electronic address: Morganbp@cardiff.ac.uk.
Abstract
PURPOSE: To explore whether complement dysregulation occurs in a routinely recruited clinical cohort of epilepsy patients, and whether complement biomarkers have potential to be used as markers of disease severity and seizure control. METHODS: Plasma samples from 157 epilepsy cases (106 with focal seizures, 46 generalised seizures, 5 unclassified) and 54 controls were analysed. Concentrations of 10 complement analytes (C1q, C3, C4, factor B [FB], terminal complement complex [TCC], iC3b, factor H [FH], Clusterin [Clu], Properdin, C1 Inhibitor [C1Inh] plus C-reactive protein [CRP]) were measured using enzyme linked immunosorbent assay (ELISA). Univariate and multivariate statistical analysis were used to test whether combinations of complement analytes were predictive of epilepsy diagnoses and seizure occurrence. Correlation between number and type of anti-epileptic drugs (AED) and complement analytes was also performed. RESULTS: We found: CONCLUSION: This study adds to evidence implicating complement in pathogenesis of epilepsy and may allow the development of better therapeutics and prognostic markers in the future. Replication in a larger sample set is needed to validate the findings of the study.
PURPOSE: To explore whether complement dysregulation occurs in a routinely recruited clinical cohort of epilepsy patients, and whether complement biomarkers have potential to be used as markers of disease severity and seizure control. METHODS: Plasma samples from 157 epilepsy cases (106 with focal seizures, 46 generalised seizures, 5 unclassified) and 54 controls were analysed. Concentrations of 10 complement analytes (C1q, C3, C4, factor B [FB], terminal complement complex [TCC], iC3b, factor H [FH], Clusterin [Clu], Properdin, C1 Inhibitor [C1Inh] plus C-reactive protein [CRP]) were measured using enzyme linked immunosorbent assay (ELISA). Univariate and multivariate statistical analysis were used to test whether combinations of complement analytes were predictive of epilepsy diagnoses and seizure occurrence. Correlation between number and type of anti-epileptic drugs (AED) and complement analytes was also performed. RESULTS: We found: CONCLUSION: This study adds to evidence implicating complement in pathogenesis of epilepsy and may allow the development of better therapeutics and prognostic markers in the future. Replication in a larger sample set is needed to validate the findings of the study.
Authors: Rodney Ogwang; Dennis Muhanguzi; Kioko Mwikali; Ronald Anguzu; Joe Kubofcik; Thomas B Nutman; Mark Taylor; Charles R Newton; Angela Vincent; Andrea L Conroy; Kevin Marsh; Richard Idro Journal: Epilepsia Open Date: 2021-03-12
Authors: Eleni Syrimi; Eanna Fennell; Alex Richter; Pavle Vrljicak; Richard Stark; Sascha Ott; Paul G Murray; Eslam Al-Abadi; Ashish Chikermane; Pamela Dawson; Scott Hackett; Deepthi Jyothish; Hari Krishnan Kanthimathinathan; Sean Monaghan; Prasad Nagakumar; Barnaby R Scholefield; Steven Welch; Naeem Khan; Sian Faustini; Kate Davies; Wioleta M Zelek; Pamela Kearns; Graham S Taylor Journal: iScience Date: 2021-10-02